HDAC3 and neoplasm: Preclinical studies have demonstrated that HDAC3 inhibitors can increase the efficacy of immune checkpoint inhibitors by reversing immune suppression and promoting a more robust anti-tumor immune response based on their effects on the tumor microenvironment by regulating immune cell infiltration and immune evasion mechanisms, which are critical for the success of immunotherapy [46].